


Integration of Advanced Orthogonal Methods for HCP Characterization

Step 1: HCP antibody and ELISA development using proper upstream source of antigen

Step 2: HCP antibody coverage analysis using AAE followed by 2D-PAGE or MS

Step 3: ELISA qualification by spike recovery, precision, and sensitivity studies



Step 4: Mass Spectrometry

- ✓ AAE enables removal of DS interference and enrichment of HCPs. While HCPs can be identified and quantified by discovery and targeted MS, mass spectrometry will fail to detect lower abundance HCPs without their enrichment.
- ✓ In the cases where there is a lack of dilution linearity by ELISA, or individual HCPs, these HCPs should be identified and quantified by mass spectrometry.
- ✓ If HCPs are identified by MS and are not being accurately quantified by the total HCP ELISA, then consider development of a mono-specific ELISA or a targeted MS method, or optimize the purification process to better remove HCPs.
- ✓ If there are no detectable individual HCPs in a DS by 2D PAGE, the ELISA shows low total HCP that is confirmed by a “reference” ELISA, and if downstream and DS samples show dilution linearity, then MS serves as a confirmatory orthogonal method.

Contact us at techsupport@cygnustechnologies.com to discuss your current and future HCP analysis projects!

Trust Your Assays. Trust Your Results.

cygnustechnologies.com

© 2019 Cygnus Technologies. All rights reserved.
For research use only. Not intended for animal or human therapeutic or diagnostic use.

 **CYGNUS**
TECHNOLOGIES
part of Marvai LifeSciences